This trial is evaluating whether Vincristine will improve 2 primary outcomes and 4 secondary outcomes in patients with Lymphoma, Primary Effusion. Measurement will happen over the course of C1D1, C1D2, C1D6, EOT, follow-up.
This trial requires 36 total participants across 2 different treatment groups
This trial involves 2 different treatments. Vincristine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About 45% of patients with lymphoma, primary effusion, develop CNS involvement during their treatment. When CNS involvement occurs, it is usually a progressive, fatal, and treatment-refractory illness, with death occurring within one month of onset. The majority of patients were women. Survival is poorer among patients with CNS involvement.
For lymphomas with very limited, bulky disease, curative treatment may be possible. PEG-IFN plus rituximab remains active against PEL. However, in lymphomas with extensive bulky disease, with an extended disease-free interval, and in patients undergoing intensive chemotherapy, cure rates are exceedingly low. PEG-IFN and rituximab and chemotherapy, regardless of the initial regimen, appear to be ineffective in controlling disease progression.
This is the largest epidemiologic study to date. The total number of cases of lymphoma, PEA in the United States is 1.5 times higher than previously documented in the literature, while the proportion of cases diagnosed in the elderly is twofold higher. Data from a recent study indicate that the numbers of patients diagnosed with PEA and lymphomas are increasing.
The risk of developing primary effusion lymphoma is increased in untreated patients with HIV and HIV-related immunodeficiency. The risk of developing other types of lymphoma is also increased. Patients should be carefully examined to find evidence of previous and comorbid lymphoproliferative disorders and be monitored during therapy for opportunistic infections and malignancies to detect other lymphomas.
Lymphoma and PEL are both serious cancers, but the outcome for PEL patients was more favorable. For PEL patients, there are currently no known common treatments. At this time, doctors have to decide how to treat PEL patients and choose the right medicine based on their patients' symptoms and physical evaluation. In addition, doctors should have a plan in case of complications, which is probably very common. Treatment options should be reconsidered once more evidence becomes available.
Some of the main signs of lymphoma, primary effusion, include fever, night sweats, weight loss, and pain in the extremities. Other key signs of lymphoma, primary effusion, include erythema nodosum, B symptom, swollen lymph nodes, and the presence of pleural effusions.
Lenalidomide is a more potent T-lymphocyte stimulator, compared with thalidomide. The mechanism of action includes downregulating Interleukin 2 expression by T cells and induction of apoptosis in T cells.
To our knowledge there is no other randomized trial-level evidence on efficacy of lenalidomide in patients with primary effusions. Therefore, the evidence base for the efficacy of lenalidomide is limited. More data on the long-term efficacy of lenalidomide are needed; studies on efficacy and safety of lenalidomide as part of combination therapies for PCML warrant investigation, especially since lenalidomide and paclitaxel plus etoposide/dexamethasone/bortezomib is currently the first line therapy for patients with B-cell non-Hodgkin lymphoma in the UK and France.
The study revealed that the disease rapidly disseminates. A patient with a diagnosis of DLBCC should be monitored in a specialist department after the last day of therapy.
These include nausea or vomiting, diarrhea, fatigue, pain, weakness, loss of appetite, and skin reactions such as hives and flushing. Lenalidomide can induce a very high level of white blood cell counts and neutropenia. Regular surveillance and monitoring of blood counts are recommended during therapy. This drug may interfere with the use of other medications or supplements that may affect the blood counts.
A recent study found that patients with a history of lymphoma have an increased incidence of PE. PE is a common cause of unexplained fever and unexplained weight loss in patients with unexplained or unexplained lymphadenopathy. Physicians may consider biopsies in patients with unexplained fevers and unexplained weight loss.